171 related articles for article (PubMed ID: 8500224)
21. Preparation and characterization of platinum(II) and (IV) complexes of 1,3-diaminepropane and 1,4-diaminebutane: circumvention of cisplatin resistance and DNA interstrand cross-link formation in CH1cisR ovarian tumor cells.
Alvarez-Valdés A; Pérez JM; López-Solera I; Lannegrand R; Continente JM; Amo-Ochoa P; Camazón MJ; Solans X; Font-Bardía M; Navarro-Ranninger C
J Med Chem; 2002 Apr; 45(9):1835-44. PubMed ID: 11960495
[TBL] [Abstract][Full Text] [Related]
22. Synthesis, structural characterization, and antitumor properties of a novel class of large-ring platinum(II) chelate complexes incorporating the cis-1,4-diaminocyclohexane ligand in a unique locked boat conformation.
Hoeschele JD; Showalter HD; Kraker AJ; Elliott WL; Roberts BJ; Kampf JW
J Med Chem; 1994 Aug; 37(17):2630-6. PubMed ID: 8064793
[TBL] [Abstract][Full Text] [Related]
23. Kinetics of tissue disposition of cis-ammine/cyclohexylamine-dichloroplatinum(II) and cisplatin in mice bearing FSaIIC tumors.
Yoshida M; Khokhar AR; Zhang YP; Thai G; Siddik ZH
Cancer Chemother Pharmacol; 1994; 35(1):38-44. PubMed ID: 7987975
[TBL] [Abstract][Full Text] [Related]
24. In vitro platinum drug chemosensitivity of human cervical squamous cell carcinoma cell lines with intrinsic and acquired resistance to cisplatin.
Mellish KJ; Kelland LR; Harrap KR
Br J Cancer; 1993 Aug; 68(2):240-50. PubMed ID: 8347478
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetic and pharmacodynamic analysis of bis-acetato-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) administered once a day for five consecutive days: a phase I study.
Kurata T; Tamura T; Sasaki Y; Fujii H; Negoro S; Fukuoka M; Saijo N
Jpn J Clin Oncol; 2000 Sep; 30(9):377-84. PubMed ID: 11095134
[TBL] [Abstract][Full Text] [Related]
26. Ammine/amine platinum(IV) dicarboxylates: a novel class of platinum complex exhibiting selective cytotoxicity to intrinsically cisplatin-resistant human ovarian carcinoma cell lines.
Kelland LR; Murrer BA; Abel G; Giandomenico CM; Mistry P; Harrap KR
Cancer Res; 1992 Feb; 52(4):822-8. PubMed ID: 1737343
[TBL] [Abstract][Full Text] [Related]
27. Combination chemotherapy involving orally administered etoposide and JM-216 in murine tumor models.
Rose WC
Cancer Chemother Pharmacol; 1997; 40(1):51-6. PubMed ID: 9137529
[TBL] [Abstract][Full Text] [Related]
28. Antitumor activity of cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-2- isopropyl-1,3-dioxolane]platinum(II), a new platinum analogue, as an anticancer agent.
Kim DK; Kim HT; Cho YB; Tai JH; Ahn JS; Kim TS; Kim KH; Hong WS
Cancer Chemother Pharmacol; 1995; 35(5):441-5. PubMed ID: 7850928
[TBL] [Abstract][Full Text] [Related]
29. Ammine/amine platinum (II) complexes effective in vivo against murine tumors sensitive or resistant to cisplatin and tetraplatin.
Siddik ZH; Thai G; Yoshida M; Zhang YP; Khokhar AR
J Cancer Res Clin Oncol; 1994; 120(10):571-7. PubMed ID: 7929527
[TBL] [Abstract][Full Text] [Related]
30. In vitro phase II comparison of the cytotoxicity of a novel platinum analog, nedaplatin (254-S), with that of cisplatin and carboplatin against fresh, human ovarian cancers.
Alberts DS; Fanta PT; Running KL; Adair LP; Garcia DJ; Liu-Stevens R; Salmon SE
Cancer Chemother Pharmacol; 1997; 39(6):493-7. PubMed ID: 9118460
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of platinol analogs using the M5076 murine sarcoma.
Rose WC
Anticancer Res; 1986; 6(4):557-62. PubMed ID: 3530116
[TBL] [Abstract][Full Text] [Related]
32. Mechanism of action of an orally administered platinum complex [ammine bis butyrato cyclohexylamine dichloroplatinum (IV) (JM221)] in intrinsically cisplatin-resistant human ovarian carcinoma in vitro.
McKeage MJ; Abel G; Kelland LR; Harrap KR
Br J Cancer; 1994 Jan; 69(1):1-7. PubMed ID: 8286188
[TBL] [Abstract][Full Text] [Related]
33. Quantitative measurement of the reduction of platinum(IV) complexes using X-ray absorption near-edge spectroscopy (XANES).
Hall MD; Daly HL; Zhang JZ; Zhang M; Alderden RA; Pursche D; Foran GJ; Hambley TW
Metallomics; 2012 Jun; 4(6):568-75. PubMed ID: 22569908
[TBL] [Abstract][Full Text] [Related]
34. Human ovarian-carcinoma cell lines and companion xenografts: a disease-oriented approach to new platinum anticancer drug discovery.
Kelland LR; Jones M; Abel G; Valenti M; Gwynne J; Harrap KR
Cancer Chemother Pharmacol; 1992; 30(1):43-50. PubMed ID: 1586979
[TBL] [Abstract][Full Text] [Related]
35. Novel trans platinum complexes: comparative in vitro and in vivo activity against platinum-sensitive and resistant murine tumours.
Goddard PM; Orr RM; Valenti MR; Barnard CF; Murrer BA; Kelland LR; Harrap KR
Anticancer Res; 1996; 16(1):33-8. PubMed ID: 8615631
[TBL] [Abstract][Full Text] [Related]
36. Cholic acid-carboplatin compounds (CarboChAPt) as models for specific drug delivery: synthesis of novel carboplatin analogous derivatives and comparison of the cytotoxic properties with corresponding cisplatin compounds.
Paschke R; Kalbitz J; Paetz C; Luckner M; Mueller T; Schmoll HJ; Mueller H; Sorkau E; Sinn E
J Inorg Biochem; 2003 Apr; 94(4):335-42. PubMed ID: 12667704
[TBL] [Abstract][Full Text] [Related]
37. Reversal of cisplatin resistance in human gastric cancer cells by a wogonin-conjugated Pt(IV) prodrug via attenuating Casein Kinase 2-mediated Nuclear Factor-κB pathways.
Chen F; Qin X; Xu G; Gou S; Jin X
Biochem Pharmacol; 2017 Jul; 135():50-68. PubMed ID: 28288821
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of cisplatin and a novel platinum polymer conjugate for drug toxicity and drug distribution in mice.
Smit T; Snyman JR; Neuse EW; Bohm L; van Rensburg CE
Anticancer Drugs; 2005 Jun; 16(5):501-6. PubMed ID: 15846115
[TBL] [Abstract][Full Text] [Related]
39. Preclinical activity of a new platinum analogue, lobaplatin, in cisplatin-sensitive and -resistant human testicular, ovarian, and gastric carcinoma cell lines.
Harstrick A; Bokemeyer C; Scharnofkse M; Hapke G; Reile D; Schmoll HJ
Cancer Chemother Pharmacol; 1993; 33(1):43-7. PubMed ID: 8269588
[TBL] [Abstract][Full Text] [Related]
40. Modification of the physicochemical and pharmacological properties of anticancer platinum compounds by commercial 5-fluorouracil formulations: a comparative study using cisplatin and carboplatin.
Fournier C; Hecquet B; Bastian G; Khayat D
Cancer Chemother Pharmacol; 1992; 29(6):461-6. PubMed ID: 1568289
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
